• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Myriad Genetics to Present at Investor Healthcare Conferences

    GLOBENEWSWIRE

    Angle Partners with Myriad Genetics

    PHARMAWEB

    Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

    GLOBENEWSWIRE

    Myriad Genetics Survey: Women Fear Screenings, Find Relief

    GLOBENEWSWIRE

    Myriad Genetics Raises 2025 Revenue Guidance Post Strong

    GLOBENEWSWIRE

    Myriad Genetics Secures New $200M Credit Facility

    GLOBENEWSWIRE

    Myriad Genetics` Q2 2025 Financial Results Due August 5

    GLOBENEWSWIRE

    Myriad Genetics Receives 2025 Great Place To Work Certification

    GLOBENEWSWIRE

    Myriad Genetics Offers Early Access to FirstGene Prenatal Screen

    GLOBENEWSWIRE

    Myriad Genetics Shares Clinical Data on Precise MRD in Cancer

    GLOBENEWSWIRE

    Myriad Genetics Showcases Research and Innovations at 2025 ASCO

    GLOBENEWSWIRE

    Myriad Genetics to Join Two Investor Healthcare Conferences

    GLOBENEWSWIRE

    Myriad Genetics Announces RiskScore Study in JCO Precision Oncolo

    GLOBENEWSWIRE

    Myriad Genetics Reports Q1 2025 Results; Updates 2025 Guidance

    GLOBENEWSWIRE

    Mental Health Medication Side Effects Hinder Help for Depression

    GLOBENEWSWIRE

    Myriad Genetics to Release Q1 2025 Financial Results on May 6

    GLOBENEWSWIRE

    Myriad Genetics Highlights MRD Data at AACR Meeting

    GLOBENEWSWIRE

    Myriad Genetics Study: Depression Patients Had Fewer Hospitalizations

    GLOBENEWSWIRE

    Myriad Genetics Announces Inducement Awards

    GLOBENEWSWIRE

    Myriad Genetics Names Brian Donnelly New Chief Commercial Officer

    GLOBENEWSWIRE

    Myriad Genetics, Gabbi to Increase Access to Cancer Risk Tools

    GLOBENEWSWIRE

    Myriad Genetics partners with PATHOMIQ for AI in oncology

    GLOBENEWSWIRE

    Myriad Genetics Reports Q4 & Full-Year 2024 Financial Results

    GLOBENEWSWIRE

    Myriad Genetics Announces Senior Leadership Transition

    GLOBENEWSWIRE

    Myriad Genetics Included in Forbes America’s Best Employers List

    GLOBENEWSWIRE

    Myriad Genetics to Release Q4 and Full Year 2024 Results on Feb 2

    GLOBENEWSWIRE

    Myriad Genetics & CancerCARE Advance MyRisk Test Access

    GLOBENEWSWIRE

    Myriad Genetics and Lumea Collaborate on Prolaris, MyRisk Tests

    GLOBENEWSWIRE

    Myriad Genetics Announces 2 New Patents Granted for its MRD Assay

    GLOBENEWSWIRE

    Myriad Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study

    GLOBENEWSWIRE

    Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

    GLOBENEWSWIRE

    Myriad Study On Cancer Risk Published In Obstetrics & Gynecology

    GLOBENEWSWIRE

    Myriad Genetics Reports Strong Growth & Future Financial Plans

    GLOBENEWSWIRE

    Myriad Genetics Teams Up With Hannah To Promote Family Cancer

    GLOBENEWSWIRE

    Myriad To Present At 43rd J.P. Morgan Health Conference

    GLOBENEWSWIRE

    Myriad Genetics to Present at 43rd Annual J.P. Morgan Conference

    GLOBENEWSWIRE

    MD Anderson And Myriad Partner On Molecular Residual Disease Assay

    GLOBENEWSWIRE

    Myriad Genetics Releases Quality & Corporate Responsibility Report

    GLOBENEWSWIRE

    Myriad Genetics RiskScore Study Named Top 10 in Genomic Medicine

    GLOBENEWSWIRE

    Myriad Updates On UnitedHealthcare Policy For Genetic Testing

    GLOBENEWSWIRE

    Myriad Genetics Elevated By NCCN Prostate Cancer Guidelines

    GLOBENEWSWIRE

    Myriad Genetics Elects Mark S. Davis To Board Of Directors

    GLOBENEWSWIRE

    NCCN Prostate Cancer Reinforce Prolaris® as `Advanced Tool`

    GLOBENEWSWIRE

    Myriad Genetics to Present Data at San Antonio Cancer Symposium

    GLOBENEWSWIRE

    Myriad Genetics Integrates HRD Platform In Illumina’s Assay

    GLOBENEWSWIRE

    Myriad Genetics Announces Prequel® Screening At 8 Weeks Pregnant

    GLOBENEWSWIRE

    Myriad Genetics Expands At-Home Fetal Sex DNA Test Retail Access

    GLOBENEWSWIRE

    Myriad Genetics Q3 2024 Results & Financial Guidance Update

    GLOBENEWSWIRE

    Myriad Genetics Comments on UnitedHealthcare’s Pharmacogenetic

    GLOBENEWSWIRE

    Myriad Genetics to Release Q3 2024 Financial Results on Nov 7, 2024

    GLOBENEWSWIRE

    Myriad Genetics And Jscreen™ Partner To Advance Health Equity

    GLOBENEWSWIRE

    Myriad Genetics And Flatiron Partner For Genetic Testing Access

    GLOBENEWSWIRE

    Myriad Recent Approvals in Cancer, The Era of Bispecifics Is Here

    BIOSPACE

    Myriad Announces Collaborate MRD Testing in Breast Cancer

    GLOBENEWSWIRE

    Myriad And Ultima To Test UG 100™ Platform For Genomic Services

    GLOBENEWSWIRE

    Myriad Genetics Third Patent Granted for Molecular Residual Disease

    GLOBENEWSWIRE

    Myriad Genetics To Share Data At NSGC 2024 Conference

    GLOBENEWSWIRE

    Myriad Genetics to Host Investor Event on October 9, 2024

    GLOBENEWSWIRE

    Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences

    GLOBENEWSWIRE

    Myriad Genetics Reports Strong Q2 2024 Results, Raises Guidance

    GLOBENEWSWIRE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.